Format

Send to

Choose Destination
See comment in PubMed Commons below
Pediatr Infect Dis J. 2016 Dec 21. doi: 10.1097/INF.0000000000001491. [Epub ahead of print]

Response to Tenofovir Among Lamivudine-Experienced Hepatitis B and HIV Coinfected Adolescents.

Author information

  • 11Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand; 2Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand; 3Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand; 4Nakornping Hospital, Chiang Mai, Thailand; 5The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), the Thai Red Cross AIDS Research, Bangkok, Thailand; and 6Department of pediatrics, Faculty of Medicine, and Research Unit in Pediatric Infectious Diseases and Vaccines, Chulalongkorn University, Bangkok, Thailand.

Abstract

We determined hepatitis B virus (HBV) suppression rates among 18 lamivudine (3TC)-experienced HBV-HIV coinfected adolescents after treatment with tenofovir disoproxil fumurate (TDF). At TDF initiation, their median age was 17.6 years, and duration of 3TC-exposure was 7.3 years. Eleven patients (61%) achieved HBV DNA <60 IU/mL after 48 weeks on TDF and 3TC which was similar to adult studies, although HBsAg loss or HBeAb seroconversion did not occur.

PMID:
28005687
DOI:
10.1097/INF.0000000000001491
[PubMed - as supplied by publisher]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Support Center